Jemperli approved in the U.S. for certain rectal cancer patients
Jemperli (dostarlimab) was approved in the U.S. for adults with MSI-H/dMMR locally advanced rectal cancer, described as the first and only immunotherapy for this indication.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.